4.5 Article

United Kingdom criteria for liver transplantation in the setting of isolated unresectable colorectal liver metastases

Journal

COLORECTAL DISEASE
Volume 25, Issue 3, Pages 489-494

Publisher

WILEY
DOI: 10.1111/codi.16446

Keywords

colorectal cancer; liver metastases; transplant

Ask authors/readers for more resources

This study aims to outline the proposed UK selection criteria and follow-up process for liver transplantation in patients with colorectal cancer liver metastases. The study provides comprehensive inclusion/exclusion criteria and explains the referral framework. Pretransplant assessment criteria and posttransplant oncology-specific outcome measures are also described. The service is anticipated to begin in December 2022, with educational events planned for 2023 to raise awareness of this newly accepted indication for transplantation in the UK.
Aim: Studies have demonstrated that liver transplantation may be an effective treatment for isolated unresectable colorectal cancer liver metastases (CRCLM). Published data suggest that 5-year survival may be as high as 80%; however, recurrent disease is commonplace. Consequently, the Liver Transplantation for Unresectable Colorectal Liver Metastases Fixed Term Working Unit recommended to the NHS Blood and Transplant Liver Advisory Group that while CRCLM is an appropriate indication for transplantation, selection criteria should be conservative and that it should be undertaken within a clinical service evaluation programme. The aim of this work is to outline the proposed UK selection criteria and follow-up process for CRCLM transplantation. Method: Consensus statement by colorectal cancer/liver transplantation patient representatives, experts in colorectal cancer surgery/oncology, liver transplantation surgery, hepatology, hepatobiliary radiology, hepatobiliary pathology and nuclear medicine. Results: This study provides a comprehensive outline of the inclusion/exclusion criteria for referral in the UK. Furthermore, the referral framework is also explained. Pretransplant assessment criteria for listing/delisting are outlined. Finally, the oncology-specific outcome measures posttransplant are described. Conclusion: It is anticipated this service will begin in December 2022. A series of educational events for the referrers and transplant units will be arranged throughout 2023 to highlight CRCLM as a newly accepted UK indication for transplantation. A national audit will be undertaken to identify patients currently on treatment who meet the criteria for transplant. Data will be collected in a national registry and reviewed on an ongoing basis to confirm the safety of this treatment and to determine if the inclusion criteria require revision.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available